An enhanced expression of CPT1 in CAVPENET-treated PCa cells was found, suggesting increased fatty acid oxidation, which is consistent with the CAVPENET-induced AKT inhibition. The gene discussed is CPT1A; the disease is posterior cortical atrophy.